BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, May 8, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 21, 2004
View Archived Issues
Pharmion Gets 'Full Approval' For Vidaza In MDS Subtypes
Pharmion Corp.'s value soared 47.8 percent Thursday after the FDA issued full approval of Vidaza, the firm's orphan drug for myelodysplastic syndromes (MDS). (BioWorld Today)
Read More
Biomira Spins Out Company To Put L-IL-2 Back In Clinic
Read More
ZymoGenetics Out-Licenses Target To Amgen For $10M
Read More
Molecular Insight $7M Series B To Advance Lead Imaging Agent
Read More
Boston Life Sciences Begins Phase III Study Of Altropane
Read More
Digestive Disease Week
Read More
Other News To Note
Read More